| A2AR/A2BR | A2A/A2B adenosine receptor |
| ADAM17 | a disintegrin and metalloproteinase 17 |
| ADCC | antibody-dependent cellular cytotoxicity |
| AHR | aryl hydrocarbon receptor |
| AKT | protein kinase B |
| AMP | adenosine monophosphate |
| AP-1 | activator protein 1 |
| ARG1/ARG2 | arginase-1/arginase-2 |
| ATP | adenosine triphosphate |
| B7 | B7 costimulatory molecules (CD80/CD86) |
| BAF180 | BRG1-associated factor 180 (product of PBRM1) |
| BAP1 | BRCA1-associated protein 1 |
| BATF | basic leucine zipper ATF-like transcription factor |
| CAF | cancer-associated fibroblast |
| cAMP | cyclic adenosine monophosphate |
| cfDNA | cell-free DNA |
| CAR | chimeric antigen receptor |
| CCL17/CCL22 | C-C motif chemokine ligand 17/22 |
| ccRCC | clear cell renal cell carcinoma |
| CD3ζ | CD3 zeta chain |
| CD39 | ectonucleoside triphosphate diphosphohydrolase-1 |
| CD73 | ecto-5′-nucleotidase |
| CDK4/6 | cyclin-dependent kinase 4/6 |
| CDKN2A/CDKN2B | cyclin-dependent kinase inhibitor 2A/2B |
| CREB | cAMP response element-binding protein |
| CSF1/CSF1R | colony-stimulating factor 1/its receptor |
| CSK | C-terminal Src kinase |
| CTLA-4 | cytotoxic T-lymphocyte-associated protein 4 |
| ctDNA | circulating tumor DNA |
| CXCL9/10/12/13 | C-X-C motif chemokine ligand 9, 10, 12, 13 |
| CXCR3/CXCR4 | C-X-C motif chemokine receptor 3/4 |
| DFS | disease-free survival |
| ECM | extracellular matrix |
| EGF | epidermal growth factor |
| EP2/EP4 | prostaglandin E receptor 2/4 |
| EPO | erythropoietin |
| ERK | extracellular signal-regulated kinase |
| ERV | endogenous retrovirus |
| FAP | fibroblast activation protein |
| FasL | Fas ligand |
| FcγR | Fc gamma receptor |
| FMT | fecal microbiota transplantation |
| FOXP3 | forkhead box P3 |
| GCN2 | general control nonderepressible 2 |
| GLUT1 | glucose transporter 1 |
| HERV-E | human endogenous retrovirus type E |
| HGF | hepatocyte growth factor |
| HIF-1α/HIF-2α | hypoxia-inducible factor 1-alpha/2-alpha |
| HLA | human leukocyte antigen |
| HR | hazard ratio |
| ICAM-1 | intercellular adhesion molecule 1 |
| ICI | immune checkpoint inhibitor |
| IDO1 | indoleamine 2,3-dioxygenase 1 |
| IFN-γ | interferon gamma |
| IgG | immunoglobulin G |
| IL-2/4/6/10/23/35 | interleukin-2, -4, -6, -10, -23, -35 |
| irAE | immune-related adverse event |
| InDel | insertion–deletion |
| iNOS | inducible nitric oxide synthase |
| ITSM | immunoreceptor tyrosine-based switch motif |
| ITT | intention to treat |
| JAK1/2 | Janus kinase 1/2 |
| KDM5C | lysine demethylase 5C |
| KIM-1 | kidney injury molecule-1 |
| Ki-67 | marker of proliferation Ki-67 |
| LAG-3 | lymphocyte-activation gene 3 |
| LCK | lymphocyte-specific protein tyrosine kinase |
| LDHA | lactate dehydrogenase A |
| LOX | lysyl oxidase |
| M-CSF | macrophage colony-stimulating factor |
| MAPK | mitogen-activated protein kinase |
| MDSC | myeloid-derived suppressor cell |
| MEK | mitogen-activated protein kinase |
| MHC | major histocompatibility complex |
| miR-23a/miR-146a | microRNA-23a/-146a |
| MMP | matrix metalloproteinase |
| mRNA | messenger RNA |
| MTAP | methylthioadenosine phosphorylase |
| mTOR/mTORC1 | mechanistic target of rapamycin (complex 1) |
| NFAT | nuclear factor of activated T cells |
| NF-κB | nuclear factor kappa B |
| NK | natural killer |
| NKG2D | natural killer group 2 member D |
| NKp30/NKp44 | natural cytotoxicity receptors 30/44 |
| NO | nitric oxide |
| OS | overall survival |
| p15INK4b/p16INK4a | cyclin-dependent kinase inhibitor proteins |
| PAD4 | peptidylarginine deiminase 4 |
| PBAF | polybromo-associated BAF |
| PBRM1 | polybromo 1 |
| PD-1 | programmed cell death protein 1 |
| PD-L1/PD-L2 | programmed death-ligand 1/2 |
| PDGF | platelet-derived growth factor |
| PFS | progression-free survival |
| PGC-1α | PPAR gamma coactivator 1-alpha |
| PGE2 | prostaglandin E2 |
| PI3K | phosphoinositide 3-kinase |
| PIK3CA | PI3K catalytic subunit alpha |
| PKA | protein kinase A |
| PPAR | peroxisome proliferator-activated receptor |
| PTEC | proximal tubular epithelial cell |
| RCC | renal cell carcinoma |
| scRNA-seq | single-cell RNA sequencing |
| SETD2 | SET domain containing 2 |
| SHP-1/SHP-2 | Src homology region 2 domain-containing phosphatase 1/2 |
| SLC11A1 | solute carrier family 11 member 1 |
| SMAD2/3 | SMAD family member 2/3 |
| SNV | single-nucleotide variant |
| STAT1/STAT3/STAT6 | signal transducer and activator of transcription 1, 3, 6 |
| SWI/SNF | switch/sucrose non-fermentable |
| TAM | tumor-associated macrophage |
| TCF-1 (TCF7) | T-cell factor 1 |
| TCR | T-cell receptor |
| TDO | tryptophan 2,3-dioxygenase |
| TEM | Tie2-expressing monocyte |
| TEX | exhausted T cell |
| TGF-β | transforming growth factor beta |
| TGF-βRII | TGF-β receptor II |
| TIGIT | T-cell immunoreceptor with Ig and ITIM domains |
| TIM-3 (HAVCR2) | T-cell immunoglobulin and mucin domain-containing protein 3 |
| TKI | tyrosine kinase inhibitor |
| TLS | tertiary lymphoid structure |
| TMB | tumor mutational burden |
| TME | tumor microenvironment |
| TNF-α | tumor necrosis factor alpha |
| TOX | thymocyte selection-associated high mobility group box protein |
| Treg | regulatory T cell |
| TRM | tissue-resident memory T cell |
| tRNA | transfer RNA |
| VCAM-1 | vascular cell adhesion molecule 1 |
| VEGF/VEGFR | vascular endothelial growth factor/its receptor |
| VHL | von Hippel–Lindau |
| WNK1 | WNK lysine deficient protein kinase 1 |
| ZAP70 | zeta-chain-associated protein kinase 70 |